MYCN and neuroblastoma: Treatment is based on pretreatment risk stratification according to the International Neuroblastoma Risk Group (INRG) staging system, which takes into account disease stage, patient's age at diagnosis, tumor histology and genetic profile (including MYCN status, segmental chromosomal aberrations and DNA ploidy).[2] Intensity of treatment and prognosis depend on this assessment, with therapeutic strategies for patients with high-risk neuroblastoma being amongst the most aggressive and longest lasting regimens in pediatric oncology.